Rational Choice of Antibiotics and Media for Mycobacterium avium Complex Drug Susceptibility Testing

被引:10
|
作者
Jaffre, Jeremy [1 ,2 ]
Aubry, Alexandra [1 ,2 ]
Maitre, Thomas [1 ]
Morel, Florence [1 ,2 ]
Brossier, Florence [1 ,2 ]
Robert, Jerome [1 ,2 ]
Sougakoff, Wladimir [1 ,2 ]
Veziris, Nicolas [1 ,2 ,3 ]
机构
[1] Sorbonne Univ, Grp Hosp Univ, Hop Pitie Salpetriere, AP HP,Ctr Natl Reference Mycobacteries & Resistan, Paris, France
[2] Sorbonne Univ, INSERM, Cimi Paris, Ctr Immunol & Malad Infect,U1135, Paris, France
[3] Sorbonne Univ, Grp Hosp Univ, Hop St Antoine, AP HP, Paris, France
关键词
drug susceptibility testing; Mycobacterium avium complex; SLOMYCO Sensititre; Mueller Hinton; clarithromycin; amikacin; IN-VITRO ACTIVITY; RANDOMIZED-TRIAL; LUNG-DISEASE; CLARITHROMYCIN; THERAPY; COMBINATION; ETHAMBUTOL; RIFABUTIN; REGIMENS; AMIKACIN;
D O I
10.3389/fmicb.2020.00081
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The Clinical and Laboratory Standards Institute recommends the use of Mueller Hinton (MH) medium to perform drug susceptibility testing (DST) of Mycobacterium avium complex (MAC) using the microdilution method. For MAC, there has been no study on the impact of media on the determination of minimum inhibitory concentrations (MICs) of antibiotics other than clarithromycin. This study aimed at determining the impact of two media used for DST of MAC and at augmenting the number of pertinent MICs for MAC species encountered in clinical practice. MICs of antibiotics used for the treatment of MAC infections were determined for 158 clinical MAC isolates (80 M. avium, 40 M. intracellulare, 35 M. chimaera, two M. yongonense and one M. timonense) in MH and 7H9 broths using the SLOMYCO Sensititre(TM) system (TREK Diagnostic Systems, East Grinstead, United Kingdom). The modal MICs determined in both media were the same for linezolid, moxifloxacin, rifabutin and amikacin but not for clarithromycin, rifampin and ethambutol. The kappa test for MICs converted to susceptibility categories showed an excellent agreement for clarithromycin, a moderate agreement for linezolid and a weak agreement for moxifloxacin and amikacin. For amikacin, 7H9 allowed a better distinction (fewer intermediate strains) of wild-type populations than MH. Existing breakpoints for linezolid and moxifloxacin are spread through the distribution of MICs for wild-type populations. The only breakpoints that can be used rationally are those for amikacin and clarithromycin. For amikacin, 7H9 performs better than MH, whereas both media perform equally for clarithromycin. Given that testing in 7H9, as opposed to MH, allows easier MIC measurements and yields greater reproducibility, we propose the use of 7H9 medium for DST of MAC.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Species identification of Mycobacterium abscessus subsp abscessus and Mycobacterium abscessus subsp bolletii using rpoB and hsp65, and susceptibility testing to eight antibiotics
    Nie, Wenjuan
    Duan, Hongfei
    Huang, Hairong
    Lu, Yu
    Bi, Dapeng
    Chu, Naihui
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 25 : 170 - 174
  • [42] Proficiency testing for drug susceptibility testing of Mycobacterium tuberculosis complex using commercial broth microdilution plate in China in 2021
    Xia, Hui
    Song, Yuanyuan
    Zheng, Yang
    Zhou, Yang
    Ou, Xichao
    Wang, Shengfen
    Zhao, Bing
    Zhao, Yanlin
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2024, 36 : 230 - 236
  • [43] Clarithromycin Susceptibility Testing of Mycobacterium avium Complex Using 2,3-Diphenyl-5-thienyl-(2)-tetrazolium Chloride Microplate Assay with Middlebrook 7H9 Broth
    Park, Young Kil
    Koh, Won-Jung
    Kim, Shin Ok
    Shin, Sonya
    Kim, Bum Joon
    Cho, Sang-Nae
    Lee, Sun Min
    Chang, Chulhun L.
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2009, 24 (03) : 511 - 512
  • [44] RADIOMETRIC AND CONVENTIONAL DRUG SUSCEPTIBILITY TESTING OF MYCOBACTERIUM-TUBERCULOSIS
    HOEL, T
    ENG, J
    APMIS, 1991, 99 (11) : 977 - 980
  • [45] Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV
    Jennifer Chu
    Caroline E Sloan
    Kenneth A Freedberg
    Yazdan Yazdanpanah
    Elena Losina
    AIDS Research and Therapy, 8
  • [46] Comparing minimum inhibitory concentrations of amikacin for pulmonary Mycobacterium avium complex disease: An analysis of culture media differences
    Morita, Atsuho
    Namkoong, Ho
    Uwamino, Yoshifumi
    Mitarai, Satoshi
    Aono, Akio
    Asakura, Takanori
    Yagi, Kazuma
    Tanaka, Hiromu
    Azekawa, Shuhei
    Nakagawara, Kensuke
    Kaji, Masanori
    Nagao, Genta
    Kamata, Hirofumi
    Matsushita, Hiromichi
    Fukunaga, Koichi
    Hasegawa, Naoki
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2024, 30 (02) : 159 - 163
  • [47] Correlation of drug exposure and bacterial susceptibility with treatment response for Mycobacterium avium complex lung disease: protocol for a prospective observational cohort study
    Zheng, Xubin
    Wang, Li
    Forsman, Lina Davies
    Zhang, Yangyi
    Chen, Yuhang
    Luo, Xuejiao
    Liu, Yidian
    Bruchfeld, Judith
    Hu, Yi
    Alffenaar, Jan-Willem C.
    Sha, Wei
    Xu, Biao
    BMJ OPEN, 2023, 13 (10):
  • [48] Crystalline nitrate reductase reagent for drug susceptibility testing of Mycobacterium tuberculosis
    Panaiotov, Stefan
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2009, 34 (02) : 191 - 192
  • [49] Inconsistencies in drug susceptibility testing of Mycobacterium tuberculosis: Current riddles and recommendations
    Varghese, Bright
    Al-Omari, Ruba
    Al-Hajoj, Sahal
    INTERNATIONAL JOURNAL OF MYCOBACTERIOLOGY, 2013, 2 (01) : 14 - 17
  • [50] Serum concentrations of clarithromycin and rifampicin in pulmonary Mycobacterium avium complex disease: Long-term changes due to drug interactions and their association with clinical outcomes
    Shimomura H.
    Andachi S.
    Aono T.
    Kigure A.
    Yamamoto Y.
    Miyajima A.
    Hirota T.
    Imanaka K.
    Majima T.
    Masuyama H.
    Tatsumi K.
    Aoyama T.
    Journal of Pharmaceutical Health Care and Sciences, 1 (1)